Lawrence E Morris
Overview
Explore the profile of Lawrence E Morris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Solomon S, Brown S, Shegda N, Jackson K, Zhang X, Bashey A, et al.
Transplant Cell Ther
. 2022 May;
28(8):486.e1-486.e7.
PMID: 35598842
Single-agent high-dose melphalan (Mel) followed by autologous stem cell transplantation (ASCT) remains a standard of care in eligible patients with multiple myeloma (MM), and efforts to improve transplant outcomes by...
12.
Brunstein C, ODonnell P, Logan B, Dawson P, Costa L, Cutler C, et al.
Transplant Cell Ther
. 2022 Apr;
28(7):406.e1-406.e6.
PMID: 35390529
We previously reported the results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1101, a randomized comparison of hematopoietic cell transplantation (HCT) performed with double umbilical cord blood...
13.
ODonnell P, Brunstein C, Fuchs E, Zhang M, Allbee-Johnson M, Antin J, et al.
Transplant Cell Ther
. 2021 Nov;
28(2):109.e1-109.e8.
PMID: 34775146
Randomized clinical trials offer the highest-quality data for modifying clinical practice. Results of a phase III randomized trial of nonmyeloablative transplantation for adults with high-risk hematologic malignancies with 2 umbilical...
14.
Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, et al.
Front Immunol
. 2021 Sep;
12:700045.
PMID: 34539628
We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma,...
15.
Solh M, Hinojosa G, Laporte J, Solomon S, Morris L, Zhang X, et al.
Adv Hematol
. 2021 Apr;
2021:8868142.
PMID: 33859695
T-replete haploidentical donor transplants using posttransplant cyclophosphamide (haplo) have greatly expanded donor availability and are increasingly utilized. Haplo were originally performed using truly nonmyeloablative conditioning and a bone marrow graft....
16.
Fuchs E, ODonnell P, Eapen M, Logan B, Antin J, Dawson P, et al.
Blood
. 2021 Jan;
137(3):420-428.
PMID: 33475736
Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB) or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct comparison of these donor...
17.
Solomon S, Aubrey M, Zhang X, Jackson K, Morris L, Holland H, et al.
Blood Adv
. 2020 Oct;
4(20):5311-5321.
PMID: 33108457
HLA disparity is the major predictor of outcome following unrelated donor (UD) transplantation, where a single mismatch (mm) at the HLA-A, HLA-B, HLA-C, or HLA-DRB1 locus leads to increased mortality,...
18.
Solh M, Speckhart D, Solomon S, Bashey A, Morris L, Zhang X, et al.
Blood Adv
. 2020 Oct;
4(19):4812-4821.
PMID: 33022065
To evaluate the impact of psychosocial risks on post-hematopoietic stem cell transplantation (HSCT) outcomes, we prospectively conducted psychosocial assessment of 556 consecutive allogeneic HSCT patients who received their first allogeneic...
19.
Solomon S, Solh M, Zhang X, Brown S, Jackson K, Holland H, et al.
Blood Adv
. 2020 Aug;
4(15):3669-3676.
PMID: 32777064
Proteasome inhibition results in extensive immunomodulatory effects that augment natural killer cell cytotoxicity and inhibit aspects of T-cell, B-cell, and dendritic cell function. We performed a phase 2 study that...
20.
Solh M, Baron J, Zhang X, Bashey A, Morris L, Holland H, et al.
Biol Blood Marrow Transplant
. 2020 Aug;
26(11):2082-2088.
PMID: 32745575
We assessed differences in presentation and response to therapy in 394 consecutive patients who developed acute or chronic graft-versus-host disease (GVHD) after receiving their first allogeneic transplantation (HSCT) from a...